Accuray Radiation Treatment Delivery System OKd by China

 Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA). The new, made in China system, is the first joint venture product and represents an important achievement on behalf of cancer patients, many of whom will need treatment with radiotherapy at least once to cure their cancer, increase the chance of cure or relieve symptoms caused by cancer1.  

https://www.prnewswire.com/news-releases/accuray-announces-approval-of-the-tomo-c-radiation-treatment-delivery-system-by-chinas-national-medical-products-administration-301944172.html